Trials / Unknown
UnknownNCT05740488
Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Zhujiang Hospital · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the efficacy and safety of apalutamide in combination with 89Sr as neoadjuvant therapy in prostate cancer with ≤10 bone metastases. The primary endpoint is PFS and the second endpoints are pCR, rPFS, PSA response, pain score, number and extent of bone metastases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apalutamide | 240mg, po, qd |
| DRUG | 89Sr | 100\~150MBq(based on weight), iv, q90d |
| DRUG | Luteinizing Hormone-Releasing Hormone Analog | sc, 3.6mg, q30d or 10.8mg, q90d |
Timeline
- Start date
- 2022-01-07
- Primary completion
- 2025-04-01
- Completion
- 2025-12-01
- First posted
- 2023-02-23
- Last updated
- 2024-03-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05740488. Inclusion in this directory is not an endorsement.